A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Blood

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 9389686
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hematopoietic growth factors in acute myeloid leukemia: supportive and priming effects.

  1997cited by this paper
• Application of myeloid growth factors in the treatment of acute myeloid leukemia

  1997cited by this paper
• Hematopoietic growth factors in acute leukemia

  1997cited by this paper
• Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.

  1996cited by this paper
• Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia.

  1996cited by this paper
• Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin

  1996cited by this paper
• Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

  1995cited by this paper
• A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).

  1995cited by this paper
• A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group.

  1995cited by this paper
• Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.

  1995cited by this paper
• GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML).

  1995cited by this paper
• A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group.

  1994cited by this paper
• Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

  1994cited by this paper
• Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand

  1994cited by this paper
• Blood. Thrombopoietin--at last.

  1994cited by this paper
• Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl.

  1994cited by this paper
• Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization.

  1994cited by this paper
• Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.

  1993cited by this paper
• The approach to the elderly patient with acute myeloid leukemia.

  1993cited by this paper
• Hematopoietic growth factors and their receptors in acute leukemia.

  1993cited by this paper
• What's new in fungal infection in leukemic patients.

  1993cited by this paper
• Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial.

  1992cited by this paper
• From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel.

  1990cited by this paper
• Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia.

  1990cited by this paper
• Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation.

  1989cited by this paper
• On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.

  1989cited by this paper
• The emergence of fungi as major hospital pathogens.

  1988cited by this paper
• Treatment of acute myeloid leukemia in elderly patients. A retrospective study

  1988cited by this paper
• Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium.

  1988cited by this paper
• Comparison of 1 + 5 DAT and 3 + 10 DAT followed by COAP or MAZE consolidation therapy in the treatment of acute myeloid leukemia: MRC ninth AML trial.

  1987cited by this paper
• Acute pulmonary decompensation due to amphotericin B in the absence of granulocyte transfusions.

  1986cited by this paper
• Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial.

  1986cited by this paper
• Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

  1985cited by this paper
• Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy.

  1985cited by this paper
• Group sequential clinical trials with triangular continuation regions.

  1983cited by this paper
• Fever and infection in leukemic patients. A study of 494 consecutive patients

  1978cited by this paper
• NEPHROTOXICITY OF AMPHOTERICIN B; EARLY AND LATE EFFECTS IN 81 PATIENTS.

  1964cited by this paper

• European guidelines on treatment and supportive measures in chronic neutropenias: A consensus between the European Hematology Association and the EuNet‐INNOCHRON COST Action based on a systematic evidence review

  2025cites this paper
• The Effects of Adding G-CSF to the Induction Therapy of Patients with AML Being Treated with the 7+3 Protocol: A Retrospective Comparative Study.

  2025cites this paper
• The Impact of Prophylactic Post-Chemotherapy G-CSF on the Relapse Rates in Patients with Acute Myeloid Leukemia: A Meta-Analysis

  2024cites this paper
• Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology

  2024cites this paper
• Double Emergency: A Case of Concurrent Heparin-Induced Thrombocytopenia and Acute Promyelocytic Leukemia

  2024cites this paper
• In reply.

  2022cites this paper
• [Management and follow-up of acute myeloblastic leukemia with translocation (8; 21). Report of one case].

  2021cites this paper
• Leukaemia: a model metastatic disease

  2021cites this paper
• Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO)

  2021cites this paper
• Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia

  2021cites this paper
• Comparison of Long-Acting G-CSF (PD-Lasta) with Short-Acting G-CSF (PD-Grastim) in Neutrophil Recovery Following Consolidation Chemotherapy with High-Dose Cytarabine in Acute Myeloid Leukemia: A Randomized Clinical Trial

  2021cites this paper
• Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis

  2021cites this paper
• A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes

  2021cites this paper
• Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars

  2021cites this paper
• Prophylaxis and Treatment of Invasive Aspergillosis: Who and How of Prophylaxis, Treatment, and New Therapies

  2020cites this paper
• Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial

  2020cites this paper
• Pharmacodynamics of romiplostim alone and in combination with pegfilgrastim on acute radiation-induced thrombocytopenia and neutropenia in non-human primates

  2020cites this paper
• Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML.

  2019cites this paper
• Thrombotic complications in adult patients with severe single coagulation factor or platelet defects – an overview

  2019cites this paper
• Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study

  2019cites this paper
• A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia

  2018cites this paper
• Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.

  2018cites this paper
• How Safe Is the Administration of Long-Acting Granulocyte Colony-Stimulating Factor in Cancer Patients?

  2018cites this paper
• Controversies Regarding Use of Myeloid Growth Factors in Leukemia.

  2017cites this paper
• Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group

  2017cites this paper
• Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events

  2017cites this paper
• Revisiting G-CSF Support for Hematologic Recovery after Autologous Transplantation in AML Patients

  2017cites this paper
• The number of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells indicates post-chemotherapy hematopoietic recovery in patients with acute myeloid leukemia

  2017cites this paper
• Impact of recommended weight-based dosing of granulocyte-colony stimulating factors in acute leukemia and stem cell transplant patients

  2017cites this paper
• A systematic literature review of the efficacy, effectiveness, and safety of filgrastim

  2017influential citation
• Intensive consolidation with G‐CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years

  2017cites this paper
• Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies.

  2017cites this paper
• JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia 1. Acute myeloid leukemia (AML)

  2017cites this paper
• Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

  2017cites this paper
• The Relationship Between Risk Factors and Survival in Adult Acute Lymphoblastic Leukemia

  2016cites this paper
• ACUTE MYELOID LEUKEMIAS ( H ERBA , SECTION EDITOR ) What Is the Optimal Induction Therapy for Younger Fit Patients With AML ?

  2016cites this paper
• Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia

  2016cites this paper
• Chemotherapy-induced neutropenia among pediatric cancer patients in Egypt: Risks and consequences.

  2016cites this paper
• What Is the Optimal Induction Therapy for Younger Fit Patients With AML?

  2016cites this paper
• Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy

  2015cites this paper
• Pegfilgrastim Improves Survival of Lethally Irradiated Nonhuman Primates.

  2015cites this paper
• Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma

  2015cites this paper
• Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.

  2015cites this paper
• Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT

  2014cites this paper
• Chemotherapy-related toxicity in childhood neoplasia.

  2014cites this paper
• Fatal stimulation of acute myeloid leukemia blasts by pegfilgrastim.

  2014cites this paper
• Treatment Options in Invasive Aspergillosis

  2014cites this paper
• Pain related to cancer treatments and diagnostic procedures: a no man's land?

  2014cites this paper
• New G-CSF agonists for neutropenia therapy

  2014cites this paper
• Immunotherapy for invasive mold disease in severely immunosuppressed patients.

  2013cites this paper
• Prophylactic use of granulocyte colony-stimulating factor after consolidation therapy with high-dose cytarabine for acute myeloid leukemia

  2013cites this paper
• Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base.

  2012cites this paper
• Effects of granulocyte-colony stimulating factor and the expression of its receptor on various malignant cells

  2012cites this paper
• Long-term safety of granulocyte colony-stimulating factor in normal donors: is it all clear?

  2012cites this paper
• Economic Analysis of Filgrastim Use for Patients with Acute Myeloid Leukaemia in the UK

  2012cites this paper
• Exogenous endothelial cells as accelerators of hematopoietic reconstitution

  2012cites this paper
• Neutropenia‐Associated Outcomes in Adults with Acute Myeloid Leukemia Receiving Cytarabine Consolidation Chemotherapy with or without Granulocyte Colony‐Stimulating Factor

  2012cites this paper
• Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia.

  2012cites this paper
• Effect of Primary Prophylactic Granulocyte-Colony Stimulating Factor Use on Incidence of Neutropenia Hospitalizations for Elderly Early-stage Breast Cancer Patients Receiving Chemotherapy

  2011cites this paper
• Biosimilars for the treatment of infectious diseases: the case of biosimilar interferons.

  2011cites this paper
• The hematopoietic growth factors in acute leukemia: a European perspective.

  2011cites this paper
• Randomized trial of 2 dosages of prophylactic granulocyte–colony‐stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia

  2011cites this paper
• Hematopoietic growth factors in older cancer patients.

  2011cites this paper
• The myeloid growth factors.

  2011cites this paper
• Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia.

  2011cites this paper
• Clofarabine with high dose cytarabine and granulocyte colony‐stimulating factor (G‐CSF) priming for relapsed and refractory acute myeloid leukaemia

  2011cites this paper
• Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients

  2011cites this paper
• Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a randomized multicenter phase III trial.

  2011cites this paper
• Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials

  2011cites this paper
• The hematopoietic growth factors in acute leukemia: U.S. perspective.

  2011cites this paper
• Efficacy of granulocyte colony stimulating factor as a secondary prophylaxis along with full-dose chemotherapy following a prior cycle of febrile neutropenia.

  2010cites this paper
• Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients.

  2010cites this paper
• Acute myeloid leukemia.

  2010cites this paper
• Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia

  2010cites this paper
• Cord blood transplantation in adults with acute myeloid leukaemia.

  2010cites this paper
• Peptide drugs to target G protein-coupled receptors.

  2010cites this paper
• A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule

  2010cites this paper
• Immunomodulation Therapy for Invasive Aspergillosis: Discussion on Myeloid Growth Factors, Recombinant Cytokines, and Antifungal Drug Immune Modulation

  2010cites this paper
• The Use of Myeloid Colony-Stimulating Factors in Hematologic Malignancies: The Role of Systematic Reviews and Meta-Analyses

  2010cites this paper
• Infections in acute myeloid leukemia: an analysis of 382 febrile episodes

  2010cites this paper
• Acute Myelogenous Leukemia Patients Are at Low Risk for Invasive Fungal Infections after High-Dose Cytarabine Consolidations and Thus Do Not Require Prophylaxis

  2010cites this paper
• Prophylactic use of granulocyte colony-stimulating factor after induction chemotherapy in patients with newly diagnosed acute myeloid leukemia may increase the complete remission rate: a meta-analysis of five randomised controlled trials

  2009cites this paper
• Prophylactic Use of Granulocyte Colony-Stimulating Factor after Chemotherapy Does Not Affect Survival Rate in Acute Myeloid Leukemia: A Meta-Analysis

  2009cites this paper
• Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?

  2009cites this paper
• Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation

  2009cites this paper
• Myeloid growth factors as anti-infective measures in children with leukemia and lymphoma

  2009cites this paper
• The role of myeloid growth factors in acute leukemia.

  2009cites this paper
• Monitoring of minimal residual disease in acute myeloid leukemia

  2009cites this paper
• Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy.

  2009cites this paper
• Filgrastim support in allogeneic HSCT for myeloid malignancies: a review of the role of G-CSF and the implications for current practice

  2009cites this paper
• Growth Factors in Acute Myeloid Leukemia

  2009cites this paper
• Randomized placebo‐controlled trial of granulocyte colony stimulating factor (G‐CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party

  2009cites this paper
• Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.

  2008cites this paper
• Keratinocyte Growth Factor‐2 Production in an ompT‐Deficient Escherichia coli K‐12 Mutant

  2008cites this paper
• A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial

  2008cites this paper
• [The therapy of acute myeloid leukemia in patients of advanced age].

  2008cites this paper
• Protein therapeutics: a summary and pharmacological classification

  2008cites this paper
• Managing Patients With Acute Myeloid Leukemia—Importance of Supportive Care Measures

  2008cites this paper
• Acute myeloid leukemia.

  2008cites this paper
• Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases

  2008cites this paper